Companies in CDL Health will benefit from adMare’s scientific and business expertise, infrastructure, and capital to drive health-related technologies to companies of scale. Vancouver and Montreal, Canada – July 16,…
Read More
New program supported by the Quebec Government and the City of Montreal looks to scale-up the province’s most promising young life sciences companies. Montreal, QC – June 29th, 2020: adMare…
June 26, 2020 – adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the appointment to its leadership team of Dr. Laura McIntosh as Venture Partner, Montreal, and…
The new company raises initial capital to develop transmembrane peptides against GPCRs to address high unmet needs. Montreal, Canada – June 8, 2020: CTI Life Sciences, along with partners adMare…
Montreal, Canada – June 4, 2020: adMare BioInnovations, Canada’s Global Life Sciences Venture, along with partners McGill University and AmorChem II Fund l.p., a leading early-stage venture capital fund, is…
Applications to the adMare Executive Institute’s 2020-2021 session are now being accepted until June 30, 2020.
The keystone principle in planning for our future is clear: while security of domestic supply is important, security of domestic knowledge is critical.
Working in partnership with adMare, Variational AI will apply generative artificial intelligence to identify already-approved medications that can be expeditiously repurposed to fast-track life-saving treatment for COVID-19 patients.
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
adMare BioInnovations & BELLUS have closed an agreement under which BELLUS has acquired full ownership of intellectual property previously licensed from adMare. BELLUS will own 100% of the BLU-5937 assets, and adMare’s remaining rights have been fully converted into equity in the company.
